Cargando…

Oxidized Low-Density Lipoprotein Drives Dysfunction of the Liver Lymphatic System

BACKGROUND AND AIMS: As the incidence of nonalcoholic steatohepatitis (NASH) continues to rise, understanding how normal liver functions are affected during disease is required before developing novel therapeutics which could reduce morbidity and mortality. However, very little is understood about h...

Descripción completa

Detalles Bibliográficos
Autores principales: Burchill, Matthew A., Finlon, Jeffrey M., Goldberg, Alyssa R., Gillen, Austin E., Dahms, Petra A., McMahan, Rachel H., Tye, Anne, Winter, Andrew B., Reisz, Julie A., Bohrnsen, Eric, Schafer, Johnathon B., D’Alessandro, Angelo, Orlicky, David J., Kriss, Michael S., Rosen, Hugo R., McCullough, Rebecca L., Jirón Tamburini, Beth A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7803659/
https://www.ncbi.nlm.nih.gov/pubmed/32961356
http://dx.doi.org/10.1016/j.jcmgh.2020.09.007
_version_ 1783635989121466368
author Burchill, Matthew A.
Finlon, Jeffrey M.
Goldberg, Alyssa R.
Gillen, Austin E.
Dahms, Petra A.
McMahan, Rachel H.
Tye, Anne
Winter, Andrew B.
Reisz, Julie A.
Bohrnsen, Eric
Schafer, Johnathon B.
D’Alessandro, Angelo
Orlicky, David J.
Kriss, Michael S.
Rosen, Hugo R.
McCullough, Rebecca L.
Jirón Tamburini, Beth A.
author_facet Burchill, Matthew A.
Finlon, Jeffrey M.
Goldberg, Alyssa R.
Gillen, Austin E.
Dahms, Petra A.
McMahan, Rachel H.
Tye, Anne
Winter, Andrew B.
Reisz, Julie A.
Bohrnsen, Eric
Schafer, Johnathon B.
D’Alessandro, Angelo
Orlicky, David J.
Kriss, Michael S.
Rosen, Hugo R.
McCullough, Rebecca L.
Jirón Tamburini, Beth A.
author_sort Burchill, Matthew A.
collection PubMed
description BACKGROUND AND AIMS: As the incidence of nonalcoholic steatohepatitis (NASH) continues to rise, understanding how normal liver functions are affected during disease is required before developing novel therapeutics which could reduce morbidity and mortality. However, very little is understood about how the transport of proteins and cells from the liver by the lymphatic vasculature is affected by inflammatory mediators or during disease. METHODS: To answer these questions, we utilized a well-validated mouse model of NASH and exposure to highly oxidized low density lipoprotein (oxLDL). In addition to single cell sequencing, multiplexed immunofluorescence and metabolomic analysis of liver lymphatic endothelial cells (LEC)s we evaluated lymphatic permeability and transport both in vitro and in vivo. RESULTS: Confirming similarities between human and mouse liver lymphatic vasculature in NASH, we found that the lymphatic vasculature expands as disease progresses and results in the downregulation of genes important to lymphatic identity and function. We also demonstrate, in mice with NASH, that fluorescein isothiocyanate (FITC) dextran does not accumulate in the liver draining lymph node upon intrahepatic injection, a defect that was rescued with therapeutic administration of the lymphatic growth factor, recombinant vascular endothelial growth factor C (rVEGFC). Similarly, exposure to oxLDL reduced the amount of FITC-dextran in the portal draining lymph node and through an LEC monolayer. We provide evidence that the mechanism by which oxLDL impacts lymphatic permeability is via a reduction in Prox1 expression which decreases lymphatic specific gene expression, impedes LEC metabolism and reorganizes the highly permeable lymphatic cell-cell junctions which are a defining feature of lymphatic capillaries. CONCLUSIONS: We identify oxLDL as a major contributor to decreased lymphatic permeability in the liver, a change which is consistent with decreased protein homeostasis and increased inflammation during chronic liver disease.
format Online
Article
Text
id pubmed-7803659
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-78036592021-01-22 Oxidized Low-Density Lipoprotein Drives Dysfunction of the Liver Lymphatic System Burchill, Matthew A. Finlon, Jeffrey M. Goldberg, Alyssa R. Gillen, Austin E. Dahms, Petra A. McMahan, Rachel H. Tye, Anne Winter, Andrew B. Reisz, Julie A. Bohrnsen, Eric Schafer, Johnathon B. D’Alessandro, Angelo Orlicky, David J. Kriss, Michael S. Rosen, Hugo R. McCullough, Rebecca L. Jirón Tamburini, Beth A. Cell Mol Gastroenterol Hepatol Original Research BACKGROUND AND AIMS: As the incidence of nonalcoholic steatohepatitis (NASH) continues to rise, understanding how normal liver functions are affected during disease is required before developing novel therapeutics which could reduce morbidity and mortality. However, very little is understood about how the transport of proteins and cells from the liver by the lymphatic vasculature is affected by inflammatory mediators or during disease. METHODS: To answer these questions, we utilized a well-validated mouse model of NASH and exposure to highly oxidized low density lipoprotein (oxLDL). In addition to single cell sequencing, multiplexed immunofluorescence and metabolomic analysis of liver lymphatic endothelial cells (LEC)s we evaluated lymphatic permeability and transport both in vitro and in vivo. RESULTS: Confirming similarities between human and mouse liver lymphatic vasculature in NASH, we found that the lymphatic vasculature expands as disease progresses and results in the downregulation of genes important to lymphatic identity and function. We also demonstrate, in mice with NASH, that fluorescein isothiocyanate (FITC) dextran does not accumulate in the liver draining lymph node upon intrahepatic injection, a defect that was rescued with therapeutic administration of the lymphatic growth factor, recombinant vascular endothelial growth factor C (rVEGFC). Similarly, exposure to oxLDL reduced the amount of FITC-dextran in the portal draining lymph node and through an LEC monolayer. We provide evidence that the mechanism by which oxLDL impacts lymphatic permeability is via a reduction in Prox1 expression which decreases lymphatic specific gene expression, impedes LEC metabolism and reorganizes the highly permeable lymphatic cell-cell junctions which are a defining feature of lymphatic capillaries. CONCLUSIONS: We identify oxLDL as a major contributor to decreased lymphatic permeability in the liver, a change which is consistent with decreased protein homeostasis and increased inflammation during chronic liver disease. Elsevier 2020-09-19 /pmc/articles/PMC7803659/ /pubmed/32961356 http://dx.doi.org/10.1016/j.jcmgh.2020.09.007 Text en © 2020 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Research
Burchill, Matthew A.
Finlon, Jeffrey M.
Goldberg, Alyssa R.
Gillen, Austin E.
Dahms, Petra A.
McMahan, Rachel H.
Tye, Anne
Winter, Andrew B.
Reisz, Julie A.
Bohrnsen, Eric
Schafer, Johnathon B.
D’Alessandro, Angelo
Orlicky, David J.
Kriss, Michael S.
Rosen, Hugo R.
McCullough, Rebecca L.
Jirón Tamburini, Beth A.
Oxidized Low-Density Lipoprotein Drives Dysfunction of the Liver Lymphatic System
title Oxidized Low-Density Lipoprotein Drives Dysfunction of the Liver Lymphatic System
title_full Oxidized Low-Density Lipoprotein Drives Dysfunction of the Liver Lymphatic System
title_fullStr Oxidized Low-Density Lipoprotein Drives Dysfunction of the Liver Lymphatic System
title_full_unstemmed Oxidized Low-Density Lipoprotein Drives Dysfunction of the Liver Lymphatic System
title_short Oxidized Low-Density Lipoprotein Drives Dysfunction of the Liver Lymphatic System
title_sort oxidized low-density lipoprotein drives dysfunction of the liver lymphatic system
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7803659/
https://www.ncbi.nlm.nih.gov/pubmed/32961356
http://dx.doi.org/10.1016/j.jcmgh.2020.09.007
work_keys_str_mv AT burchillmatthewa oxidizedlowdensitylipoproteindrivesdysfunctionoftheliverlymphaticsystem
AT finlonjeffreym oxidizedlowdensitylipoproteindrivesdysfunctionoftheliverlymphaticsystem
AT goldbergalyssar oxidizedlowdensitylipoproteindrivesdysfunctionoftheliverlymphaticsystem
AT gillenaustine oxidizedlowdensitylipoproteindrivesdysfunctionoftheliverlymphaticsystem
AT dahmspetraa oxidizedlowdensitylipoproteindrivesdysfunctionoftheliverlymphaticsystem
AT mcmahanrachelh oxidizedlowdensitylipoproteindrivesdysfunctionoftheliverlymphaticsystem
AT tyeanne oxidizedlowdensitylipoproteindrivesdysfunctionoftheliverlymphaticsystem
AT winterandrewb oxidizedlowdensitylipoproteindrivesdysfunctionoftheliverlymphaticsystem
AT reiszjuliea oxidizedlowdensitylipoproteindrivesdysfunctionoftheliverlymphaticsystem
AT bohrnseneric oxidizedlowdensitylipoproteindrivesdysfunctionoftheliverlymphaticsystem
AT schaferjohnathonb oxidizedlowdensitylipoproteindrivesdysfunctionoftheliverlymphaticsystem
AT dalessandroangelo oxidizedlowdensitylipoproteindrivesdysfunctionoftheliverlymphaticsystem
AT orlickydavidj oxidizedlowdensitylipoproteindrivesdysfunctionoftheliverlymphaticsystem
AT krissmichaels oxidizedlowdensitylipoproteindrivesdysfunctionoftheliverlymphaticsystem
AT rosenhugor oxidizedlowdensitylipoproteindrivesdysfunctionoftheliverlymphaticsystem
AT mcculloughrebeccal oxidizedlowdensitylipoproteindrivesdysfunctionoftheliverlymphaticsystem
AT jirontamburinibetha oxidizedlowdensitylipoproteindrivesdysfunctionoftheliverlymphaticsystem